Search / Trial NCT06225297

Evaluation of a Package of Interventions to Reduce the Burden of Malaria in the Urban Daaras of Touba, Senegal

Launched by PATH · Jan 17, 2024

Trial Information

Current as of October 04, 2024

Unknown status

Keywords

Description

In Senegal, young children (mostly boys) may be sent to religious schools (daaras) to learn about the Koran and moral and cultural values. The students (talibés) often live and sleep in crowded conditions and as a result, insecticide-treated net (ITN) use is consistently low due to challenges faced in hanging ITNs as well as difficulty covering multiple children sleeping together. This study will consist of a two-arm cluster-randomized controlled trial to evaluate the effectiveness of an intervention package in urban daaras in Touba City, Diourbel region, Senegal. The intervention package ...

Gender

ALL

Eligibility criteria

  • Inclusion criteria for daara:
  • * Located within the catchment area of Touba Health District
  • * Located within the catchment area of a health facility with an annual malaria incidence of ≥ 25 cases per 1000 population
  • * Daara is registered in the health system and the Serigne daara (i.e., daara leader) can provide caregiver consent for taalibé.
  • * Taalibé population between 50 to 100
  • * PECAdaara model has been integrated and fully operational
  • * Willingness of daara leader to participate in the study
  • Inclusion criteria for receiving SMC with DHA-PQ:
  • * Age ≥ 3 months
  • * Taalibé of study daara
  • * Willingness to comply with study procedures
  • * Provision of informed consent/assent
  • Additional inclusion criteria for receiving meganets:
  • - Sleeping in a superimposed area with ≥ 2 people
  • Exclusion Criteria:
  • * Age \< 3 months
  • * Refusal of informed consent
  • * Concomitant or recent use of antimalarials within the past two weeks
  • * Known allergy or hypersensitivity to DHA-PQ
  • * Confirmed diagnosis of clinical malaria
  • * Currently taking anti-worm or anti-infection drugs, including cotrimoxazole (BACTRIM), mebendazole, quinolones, sulfonamides (FANSIDAR, MALOXINE), dapsone, colchicine
  • * Currently taking medications that influence cardiac function or prolong the QTc interval
  • * Serious or chronic illness, including known HIV infection, heart disease, or severe malnutrition (weight-for-age or mid-upper arm circumference (MUAC) \< 3 SD)
  • * Pregnancy (assessed by history or urine pregnancy test)

About Sponsor

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Touba, , Senegal

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0